OncoMatch/Clinical Trials/NCT06386146

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Is NCT06386146 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including JAB-30355 and JAB-30355 for solid tumors.

Phase 1/2RecruitingJacobio Pharmaceuticals Co., Ltd.NCT06386146Data as of May 2026

Treatment: JAB-30355 · JAB-30355 — This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Biomarker criteria

Required: TP53 y220c

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Lab requirements

Blood counts

adequate hematological function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Cardiac function

lvef >50% assessed by echo or muga; qtcf ≤470 msec

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Research Site · Denver, Colorado
Research site · Lake Mary, Florida
Research site · St Louis, Missouri
Research site · Canton, Ohio
Research site · Cleveland, Ohio

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify